Skip to main
ROIV

ROIV Stock Forecast & Price Target

ROIV Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 63%
Buy 25%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Roivant Sciences Ltd is experiencing a positive outlook due to its robust pipeline of drug candidates, particularly the successful Phase 3 results of brepocitinib for dermatomyositis, which is projected to disrupt the current market dominated by cumbersome intravenous therapies. The recent revision of revenue estimates for IMVT-1402 in Graves' Disease underscores the strong market positioning and competitive efficacy of Roivant's drug portfolio. Additionally, the unique disease-modifying potential of batoclimab positions Roivant favorably in the growing competitive landscape, further enhancing investor confidence in the company's capability for successful commercialization and long-term growth.

Bears say

Roivant Sciences Ltd faces a negative outlook primarily due to the failure of several key drug candidates, notably brepocitinib and IMVT assets, in critical clinical trials, which raises concerns about the company's capability to deliver successful therapeutics. This is compounded by ongoing challenges in the development of other treatments within its pipeline, particularly for high-unmet need indications, which could diminish investor confidence and future revenue streams. Additionally, the risks associated with off-target effects in mechanisms like TSHR antagonism further complicate the therapeutic landscape, suggesting potential setbacks in drug efficacy and safety profiles.

ROIV has been analyzed by 8 analysts, with a consensus rating of Buy. 63% of analysts recommend a Strong Buy, 25% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Roivant Sciences Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Roivant Sciences Ltd (ROIV) Forecast

Analysts have given ROIV a Buy based on their latest research and market trends.

According to 8 analysts, ROIV has a Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.31, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.31, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Roivant Sciences Ltd (ROIV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.